The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, ...